FDA Proposes Rule to Enhance Diversity Data in Drug Applications

Summary

The US Food and Drug Administration (FDA) is proposing to update its regulations to require drug manufacturers to submit more detailed demographic data on the effectiveness and safety of their products, including age, gender, and racial subgroups, in their New Drug Applications (NDAs) and Investigational New Drug Applications (INDs).